Medical Condition News

RSS

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.

31 Jan 2014

Boehringer Ingelheim, DCRI partner to uncover insights into idiopathic pulmonary fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute have formed a unique collaborative relationship to uncover insights into idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.

31 Jan 2014

Scientists discover potential cure for triple negative breast cancer

Scientists have discovered a potential cure for one of the most aggressive and least treatable forms of breast cancer called "triple negative breast cancer." In laboratory experiments involving human cancer cells, scientists used a virus similar to the one that helped eradicate smallpox to coax cancer cells to produce a protein which makes them susceptible to radioactive iodine.

31 Jan 2014

More than 1/3 of women experience hot flashes for 10 years after menopause

A team of researchers from the Perelman School of Medicine at the University of Pennsylvania has found that moderate to severe hot flashes continue, on average, for nearly five years after menopause, and more than a third of women experience moderate/severe hot flashes for 10 years or more after menopause.

31 Jan 2014

Look to heart shaped foods to protect heart

The crumbs from the Christmas cookies are gone and black-eyed peas, eaten on New Year to bring luck, are a distant memory. Declared American Heart Month with Valentine's Day smack dab in the middle, February is here. What to eat to keep your heart healthy?

31 Jan 2014

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common form of liver cancer to develop from liver cells.

31 Jan 2014

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.

31 Jan 2014

UC San Diego researchers uncover causes for hereditary spastic paraplegia

In a study published in the January 31, 2014 issue of Science, an international team led by scientists at the University of California, San Diego School of Medicine report doubling the number of known causes for the neurodegenerative disorder known as hereditary spastic paraplegia. HSP is characterized by progressive stiffness and contraction of the lower limbs and is associated with epilepsy, cognitive impairment, blindness and other neurological features.

31 Jan 2014

Finding could lead to new treatments for osteoporosis

Scientists at Washington University School of Medicine in St. Louis have discovered what appears to be a potent stimulator of new bone growth. The finding could lead to new treatments for osteoporosis and other diseases that occur when the body doesn't make enough bone.

31 Jan 2014

TSRI scientists awarded grant to develop new therapeutic approaches for lung cancer

Scientists from the Florida campus of The Scripps Research Institute have been awarded approximately $1.8 million from the National Cancer Institute of the National Institutes of Health to identify the signaling pathways that underlie lung cancer and to use this information to develop new therapeutic approaches.

30 Jan 2014

Depression in childhood may increase risk of heart problems later in life

Children with depression are more likely to be obese, smoke and be inactive, and can show the effects of heart disease as early as their teen years, according to a newly published study by University of South Florida Associate Professor of Psychology Jonathan Rottenberg.

30 Jan 2014

Third-hand smoke as deadly as first-hand smoke

Do not smoke and do not allow yourself to be exposed to smoke because second-hand smoke and third-hand smoke are just as deadly as first-hand smoke, says a scientist at the University of California, Riverside who, along with colleagues, conducted the first animal study of the effects of third-hand smoke.

30 Jan 2014

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched a series of NeoTYPE cancer profiling tests covering 22 different categories of cancer. Each of these tests is designed to investigate the most common and actionable genomic abnormalities reported for that particular tumor.

30 Jan 2014

Checklists and feedback for ambulance crews improve care for heart attack and stroke patients

The introduction of checklists and better feedback for ambulance crews as part of a national quality improvement project has significantly improved the standard of care for heart attack and stroke patients across England, a major new study has shown.

30 Jan 2014

Not all children, young adults treated achieve long-term relief from symptoms of anxiety

Fewer than one in two children and young adults treated for anxiety achieve long-term relief from symptoms, according to the findings of a study by investigators from the Johns Hopkins Children's Center and five other institutions.

30 Jan 2014

American Cancer Society, SU2C partner to fight against cancer

The American Cancer Society, the largest voluntary health organization in the world dedicated to eliminating cancer, and Stand Up To Cancer, the charitable initiative supporting groundbreaking research aimed at getting new treatments to patients in an accelerated timeframe, announced today an historic collaboration in the fight against cancer, which takes more than 585,000 lives in the U.S. each year and nearly 8 million worldwide.

30 Jan 2014

New molecule could help lower diabetic patients' risk of developing dementia or Alzheimer's

Researchers at the Hebrew university of Jerusalem have created a molecule that could potentially lower diabetic patients' higher risk of developing dementia or Alzheimer's disease.

30 Jan 2014

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.

30 Jan 2014

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.

30 Jan 2014

Heart transplantation continues to be "gold standard" treatment for end-stage heart failure

Heart transplantation continues to be the "gold standard" treatment for end-stage heart failure, and a large number of patients now live 20 years or more after surgery, according to a study in the February 2014 issue of The Annals of Thoracic Surgery.

30 Jan 2014

Medical Condition News

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Boehringer Ingelheim, DCRI partner to uncover insights into idiopathic pulmonary fibrosis

Scientists discover potential cure for triple negative breast cancer

More than 1/3 of women experience hot flashes for 10 years after menopause

Look to heart shaped foods to protect heart

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

UC San Diego researchers uncover causes for hereditary spastic paraplegia

Finding could lead to new treatments for osteoporosis

TSRI scientists awarded grant to develop new therapeutic approaches for lung cancer

Depression in childhood may increase risk of heart problems later in life

Third-hand smoke as deadly as first-hand smoke

NeoGenomics validates and launches series of NeoTYPE cancer profiling tests

Checklists and feedback for ambulance crews improve care for heart attack and stroke patients

Not all children, young adults treated achieve long-term relief from symptoms of anxiety

American Cancer Society, SU2C partner to fight against cancer

New molecule could help lower diabetic patients' risk of developing dementia or Alzheimer's

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Heart transplantation continues to be "gold standard" treatment for end-stage heart failure

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News